Biotech Website Design: Biotech Web Design for Platforms, Pipelines, Investors and Life Science Companies

Updated October 2026 · Written and maintained by the Progression Agency strategy team

Biotech website design is the build of a site that has to explain hard science to investors, partners, scientists and future hires at once, and say only what the company’s data and regulators allow. Web design for biotech differs from ordinary business sites because the pipeline is investigational, investor pages follow disclosure rules, and the best candidates read the science before they apply. This page covers what a biotech company website needs at each stage, how pipeline and investor pages are handled, life science website design for tools, CRO and CDMO companies, and what a build costs. We design and build biotech and life science websites, starting with a free proposal and a written scope.

What is biotech website design?

Biotech website design is the planning, writing, design and build of the site a biotech company uses as its public record: what the platform does, what is in the pipeline, who the team is and how to reach them. A biotech company website is read by more kinds of people than most business sites, and each arrives with a different test in mind. A clinic site sells appointments, which is the work of healthcare website design, and the ongoing promotion of a company is the work of life sciences marketing. This page covers the build: structure, wording limits, design, platform and cost.

Who reads a biotech site

Five kinds of reader land on the same domain. Investors and analysts check the stage, the data and the team. Partners and business development staff look for the platform and the assets on offer. Scientists and candidates read the mechanism and the publications. Journalists want a press page. Patients and caregivers arrive from a condition search or a study listing and need plain words. A page written for only one of them leaves the others to guess.

What the site has to prove in the first minute

A visitor should be able to say, after one screen, what the platform is, what stage the company has reached and who is behind it. That means one plain sentence about the platform, a stage label the company can support, named leadership and a way to get in touch. Funding and partners belong on the page only as the company itself states them, in its own releases, because an investor will compare the page with the filings.

How this differs from a clinic or hospital site

A clinic site is built around a local patient who wants an appointment this week. A biotech site is built around a platform, a scientific argument and a set of institutional readers who may never book anything. The calls to action change from book a visit to contact business development, read the paper or see open roles, and the claims are governed by rules on investigational products rather than by patient advertising norms.

Biotech web design by company stage

Biotech web design starts with the stage, because the stage decides which pages are honest. A seed company has a platform and a plan; a clinical-stage company has studies and a pipeline; a commercial company has approved products with their own advertising rules. A company whose lead product is a device follows a different path, covered in our guide to medical device website design.

Seed and Series A: a site that raises and recruits

The early site has two audiences who decide fast: investors reading before a meeting and scientists deciding whether to leave a job. It needs the platform page, the founders and advisers, a science section, a careers page and a contact route. Anything about results should come from published work or the company’s own releases. If you are building one of these, our startup website design page covers the general launch questions, and this page adds the biotech wording and review limits. A biotech startup website can start small, as long as the structure leaves room to add trial and investor pages.

Clinical stage: pipeline, trials and investors

Once studies are running, the site gains a dated pipeline, a page for each registered study and an investor section. The pipeline is the page most likely to go stale or to say too much, so it gets a named owner and a review step. Study pages link to the public registry record rather than repeating its details, which keeps one source of truth. Press and events pages start to matter because journalists and analysts check them.

Commercial stage: corporate site beside branded product sites

After approval a company usually runs a corporate site for investors, candidates and partners next to one or more branded product sites for patients and prescribers. The branded sites follow prescription drug advertising rules and are a separate build, covered by our pharma web design page. The corporate site stays focused on the company: science, pipeline, leadership, careers and investors.

Explaining the science without dumbing it down

Scientific website design has one rule that general web design can skip: a specialist will check the page against what they know. The aim is to make the explanation clear to a smart outsider and still correct to an expert. That is usually a layered page, with a plain summary first and the detail one click down.

Platform and mechanism pages

The platform page should state the problem, the approach and what is different, in that order, with a figure that does real work. A short summary comes first, then the mechanism, then links to the papers behind it. Avoid adjectives that a reviewer would have to defend. If the company names a first indication, say so as the company has stated it elsewhere, and keep the date of the information visible.

Figures, animation and data visualization

Diagrams of a mechanism, a short animation of how a therapy works or a chart of assay results can carry more than text, if they are accurate and accessible. Each figure needs a caption that stands alone, a text description for people who cannot see it and a reviewer who has checked the labels and units. We can direct illustration and animation work with the company’s scientists, and the scope for it is written into the proposal.

Publications, posters and presentations library

A library of papers, posters and talks tells a scientist that the work is real. Organize it by program or topic rather than by year alone, link to the publisher’s page for each paper, and keep the posters as accessible documents rather than image-only files. Add a date and a short plain sentence on why each item matters.

Writing for a scientist and an investor on one page

The two readers want different things from the same paragraph. The scientist wants the method and the limits; the investor wants the milestone and what comes next. Put a short plain statement first, then a labeled “for scientists” detail block, and keep forward-looking statements out of the science pages, so the investor section can carry the wording the company’s counsel has approved.

Pipeline pages and the investigational line

A pipeline page lists the programs, their targets, their phases and where they stand. It is also the page where a biotech site can cross a line it does not see, because the rules treat promotion of an investigational product differently from the exchange of scientific information. This section restates what the primary texts say and leaves interpretation to the company’s counsel and regulatory advisers. For a product that has been approved, the branded site belongs to pharma web design, and prescriber outreach belongs to HCP marketing.

What 21 CFR 312.7 means for a pipeline page

The rule, 21 CFR 312.7, says that a sponsor or investigator, or anyone acting on behalf of either, shall not represent in a promotional context that an investigational new drug is safe or effective for the purposes for which it is under investigation, or otherwise promote the drug. It adds that it is not intended to restrict the full exchange of scientific information about the drug, including dissemination of scientific findings in scientific or lay media, and that its intent is to restrict promotional claims of safety or effectiveness for a use under investigation and to preclude commercialization before approval. In practice, a pipeline page describes the program, the target and the phase without words such as safe or effective, and the company’s regulatory reviewer reads every sentence. This is a restatement of the text, not advice on how it applies to your program.

Investigational devices

Devices have a parallel rule. 21 CFR 812.7 says a sponsor, investigator or anyone acting for either shall not promote or test market an investigational device until FDA has approved it for commercial distribution, and shall not represent that the investigational device is safe or effective for the purposes for which it is being investigated. A company with an investigational device on its pipeline page faces the same editing task: describe, date and attribute, and leave the judgment to the data.

Pipeline charts that stay accurate

A pipeline chart is a table with bars, and it goes wrong the same ways a table does. Use the phase labels as the company states them elsewhere, never a rounder word. Put a visible “last reviewed” date on the chart. Name the person who approves a change, and make the chart editable by that person without a developer, so a new phase is not waiting on a ticket. Give the chart a text version, because a bitmap of a pipeline is invisible to a screen reader and to search.

Can a pipeline page share scientific data?

The text of 21 CFR 312.7 says it is not intended to restrict the full exchange of scientific information about the drug, including dissemination of scientific findings in scientific or lay media. A pipeline page can therefore link to a published paper or a poster and describe findings as findings, attributed and dated. What it cannot do, in the rule’s words, is represent in a promotional context that the drug is safe or effective for the purposes under investigation. Where a data statement shades into that claim is a question for the company’s regulatory reviewer, so present data as science and not as a sales argument.

After approval: prescription drug advertising rules

Once a product is approved, its advertising falls under a separate body of rules. 21 CFR Part 202 is titled Prescription Drug Advertising, and its section 202.1 sets out requirements for prescription drug advertisements. That is a reason to treat branded product sites as their own build, planned with the company’s promotional review process, and not as a section added to the corporate site. We stop at the point where the rules begin and name the build that picks up there.

Investor relations pages

An investor section is where a public biotech’s website meets securities rules, and where a private company shows that it is ready to be looked at. It should be easy to find, plainly organized and stable, because people return to it. The company’s counsel and investor relations advisers decide what is published and when; the web build gives them a place to publish it.

Press releases, SEC filings and events

The usual building blocks are a press release archive, a filings list, a calendar of presentations and conferences, a leadership page and a contact for investor questions. Each release gets its own permanent page with the date and the full text, so it can be cited and indexed. Event pages should keep the slides or recording after the event, with the date shown, so the history is complete.

Regulation FD and the website

Regulation FD is 17 CFR Part 243, and its first section is titled General rule regarding selective disclosure. As the text reads, when an issuer, or a person acting for it, discloses material nonpublic information to certain people such as broker-dealers and investment advisers, the issuer must make public disclosure, simultaneously for an intentional disclosure and promptly for a non-intentional one. Section 243.101 defines public disclosure as furnishing or filing a Form 8-K, or using another method reasonably designed to provide broad, non-exclusionary distribution of the information. Whether a given website post counts, and when to publish it, is a question for the company’s counsel; we build the pages and the publishing workflow, and counsel decides what goes through them.

Does a private company need an investor section?

Regulation FD defines an issuer by registration under section 12 or reporting under section 15(d) of the Exchange Act, so a private company’s position differs from a public company’s, and its counsel says what applies. Many private companies still publish a short section for investors and partners with an overview, leadership, news and a contact, and it can grow into a full investor relations site if the company later reports publicly.

IR feeds and third-party IR platforms

Many public companies feed their press releases, filings and stock information from a third-party investor relations platform into the site. The build question is how that feed is embedded, how it is styled to match the site, whether the content is indexable and who owns the accounts. We plan the integration around the platform the company already uses, and where there is none, a simple native archive may be enough.

Careers pages that recruit scientists

Strong candidates read the science before they apply, so the careers page is part of the science site and not an afterthought. It should show the teams, the work and the place, then list the roles.

Roles, teams and the lab

A list of titles tells a candidate little. Tie each role to a team page that says what the team is working on and what a first year looks like, and add photographs of the real lab and the real people. A scientist wants to see the bench, the instruments and the colleagues. Link each role to the relevant publications so the candidate can read the team’s work before the interview.

Benefits, location and visa questions candidates ask

Candidates tend to ask the same practical questions: where is the lab, is relocation possible, what is the work arrangement, and does the company sponsor visas. The page can answer those that the company has decided and say plainly that it will discuss the rest. It should not make legal claims about visa processes; the company’s HR and counsel own that wording.

Applicant tracking integrations

Most companies already use an applicant tracking system. The site can embed its job feed, link to its application forms or sync listings into native pages, and each choice affects speed, design control and search visibility. Native listing pages with structured job data tend to give the most control, while an embedded frame gives the least; we scope the option to the system in use.

Clinical trial pages and patient recruitment

Trial pages serve two audiences: patients and physicians looking for a study, and everyone else checking that the program is real. The first needs plain language and a clear route; the second needs the registry record.

Linking every study to its ClinicalTrials.gov record

ClinicalTrials.gov is where study record managers submit registration and results information, and each registered study has its own record with an NCT identifier. A trial page on the company site should name the study, summarize it in plain words and link to that record, so the registry stays the single source for details such as sites and status. Repeating those details on the company page invites a mismatch the day a status changes.

Recruitment pages and IRB review

FDA’s information sheet Recruiting Study Subjects (January 1998) says an institutional review board should review the methods and material investigators propose to use to recruit subjects. It treats direct advertising for subjects as the start of the informed consent and subject selection process. It says no claims should be made that the product is safe or effective for the purposes under investigation, that advertisements should not use terms such as new treatment or new drug without explaining the product is investigational, and that they should not promise free medical treatment when the intent is only to say subjects will not be charged. It also says IRB review is not required for internet listings of clinical trials in a system whose format limits the information to basic trial information, such as the title, purpose, protocol summary, basic eligibility criteria, site locations and contact details. Which pages need review for a given study is a decision for the sponsor and the IRB; ask the IRB which recruitment materials it must see before the pages go live.

What belongs on a clinical trial page?

A plain title, a short statement of purpose, a summary of who can take part, a link to the registry record for locations and status, and a contact route. Leave out claims about benefit or comparison with other treatments. FDA’s information sheet says advertising to recruit subjects should be limited to the information prospective subjects need to decide on eligibility and interest, and lists items that may be included when appropriately worded, such as the condition under study or the purpose, summary eligibility criteria, the time or other commitment, and the location and the person or office to contact.

Patient and caregiver language

Patients and caregivers read at a different level from investors and often arrive anxious. Write short sentences, explain terms the first time, show who can take part in plain criteria and give a phone number or form for questions. Avoid wording that implies a benefit, and keep the layout calm and readable on a phone.

Life science website design for tools, CRO and CDMO companies

Life science website design for a company that sells instruments, reagents or services is closer to B2B product marketing than to a pipeline story. A life science website design company has to organize technical content, support a quote or sample request and be exact about how products may be used. The broader build principles are in our B2B website design guide, and the promotional work around it is covered under life sciences marketing.

Research Use Only labels on product pages

Some products, especially diagnostic kits and reagents, are labeled for research use only. FDA’s guidance Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only (November 2013) describes the current thinking of the Center for Devices and Radiological Health and the Center for Biologics Evaluation and Research on when in vitro diagnostic products are properly labeled for research use only or for investigational use only. For the website, that means the label belongs on the product page where a buyer sees it, the page copy must match it, and the company’s regulatory lead decides the wording.

Catalogs, specifications and technical documents

Buyers compare specifications. A product page should show the item number, the specifications, the intended use label and the documents a lab manager needs, such as data sheets, safety data sheets and certificates the company holds. Search by item number and application matters more than a clever menu. Keep documents as text-readable files rather than scans, and give each one a stable address so links from papers and protocols keep working.

Service pages for CROs and CDMOs: capabilities, sites and quality

A contract research or development and manufacturing organization sells capacity and trust. The service pages should list capabilities in the buyer’s own terms, name the sites and what each does, describe the quality system in the company’s words and show the people a sponsor will meet. Certifications and inspection history appear only when the company supplies them and can support them; we do not add claims of our own.

Design, accessibility and performance

A biotech site is judged by its look as well as its claims, and the design signals the same credibility the science does. Accessibility and speed belong in the design stage, not after it. Our ADA compliant website design page goes further on accessibility for any business.

Imagery: real labs and people, not stock beakers

Stock photographs of glassware and blue-lit double helixes say nothing, and scientific readers notice. Real laboratory photographs, portraits of the team and honest images of the instruments do more. Our fixed price table includes photography direction on the business site and content program tiers. If an image shows a process, a scientist should confirm that it shows it correctly, down to the labels and the equipment.

Accessibility

The Department of Justice’s guidance on web accessibility and the ADA (March 2022) says the ADA applies to businesses open to the public, that DOJ has no regulation setting detailed technical standards for web content, and that existing standards such as the Web Content Accessibility Guidelines can help. Its examples of barriers include poor color contrast, missing text alternatives on images, no captions on videos, inaccessible forms and no keyboard navigation. We build to WCAG 2.2 level AA; our published price table lists it in every tier. Scientific figures need particular care: every chart, diagram and animation gets a text alternative that conveys what it shows.

How accessible do science figures need to be?

Every figure should carry a text alternative that conveys its purpose; the DOJ guidance describes good alternative text as short and descriptive. A complex chart needs a longer description or a data table beside it. Color alone should not carry meaning, which the guidance lists among its examples of barriers, videos need captions, and anyone who cannot use a mouse should be able to reach every interactive chart from the keyboard.

Speed and Core Web Vitals on image-heavy science pages

Science pages are heavy with figures, and heavy pages load slowly. Google describes Core Web Vitals as metrics for loading, interactivity and visual stability, and suggests aiming for a Largest Contentful Paint within 2.5 seconds, an Interaction to Next Paint under 200 milliseconds and a Cumulative Layout Shift under 0.1. Practical steps are properly sized images, vector figures where possible, deferred loading for animations and no layout jumps when a chart appears.

CMS, review workflow and security

A biotech site changes often, by many hands, and each change may need approval. The platform should make that easy and leave a record. This section covers how we think about the content system, the review path and the hosting around it.

Choosing a CMS a communications team can run

The right content system is the one the company’s communications and investor relations staff can run without a developer for every edit. WordPress, covered on our WordPress website design page, suits most companies, and a headless setup suits teams with engineers and many channels. Decide first who edits what, then choose the platform that fits those roles.

Legal, regulatory and medical review before publishing

Pages about the pipeline, the science and investors should pass named reviewers before they go live. The site can support that with a staging copy, role-based permissions, drafts that are not public and a version history showing who changed what and when. The reviewers are the company’s, and we configure the workflow around them. Our website design page describes testing on a staging site before launch and recorded training for your editors; the review roles themselves are for the company to name.

Hosting, backups and access control

The basics are managed hosting, tested backups, two-factor login for every editor, least-privilege roles and prompt removal of access when someone leaves. We make no certification claims of our own, such as SOC 2, ISO or HIPAA; if a company’s procurement team requires a specific attestation from the host, that is a hosting decision we make with the company. The ongoing patching and monitoring side is covered on our website maintenance page.

Who should own the website inside a biotech company?

One named owner, usually in communications or investor relations, with a named backup. The owner schedules reviews, collects approvals and holds the accounts for the company. A site owned by an outside agency or by one busy scientist is a common way for pages to go stale. Our deliverables list puts the accounts in your name, and the owner is the person who holds them.

Search and AI answers for biotech sites

People find biotech companies by name, by platform terms and by condition, and increasingly through answer engines that quote pages. A site helps by stating consistent company facts, using clear headings and marking up what it can. Ongoing search work for pharma and biotech is covered by pharma SEO and AEO for pharma; this section covers the build-time foundations.

Organization markup and consistent company facts

Google’s documentation on Organization structured data says that adding it to the home page can help Google better understand an organization’s administrative details and disambiguate it in search results, and that no properties are required. The company name, address, logo and official profile links should match everywhere they appear, on the site, in filings and on press pages.

Dataset markup for public data

Google’s Dataset structured data documentation says that markup helps datasets appear in Dataset Search and names life sciences among the fields it is meant to serve. It only suits a real public dataset with a name, a description, a creator and a download or access path. A company that publishes sequencing, screening or other data can use it; a company that does not should skip it.

Pages that answer what people ask about the platform

Answer engines and searchers ask direct questions: what does the company do, what is the mechanism, which conditions are in study, who leads the team. Each of those should have a short, plain answer on a page with a clear heading, written so the sentence still makes sense when quoted alone. Keep the wording identical to the company’s other public statements.

What the best biotech website design has in common

Galleries of biotech websites tend to reward looks. The sites that serve a company well share structure more than style, and this list is about structure. We do not name or rank any company’s site. People searching for the best biotech websites are usually looking for one of two things, an idea to copy or a standard to meet, and the second is the more useful. The best biotech website design starts from these seven habits.

Why these matter more than the look

Each habit answers a question a skeptical reader asks. Can I say what they do? Is this current? Who are these people? Can I read the work? Are they hiring for real? Can I find the investor information? Can everyone use it? A site that passes on all seven can survive a plain design; a site that fails on them cannot be rescued by a good look.

Biotech website development: timeline and handover

Biotech website development covers the technical build after the design is agreed: templates, the content system, integrations such as an investor feed or applicant tracking, accessibility and performance work, and launch. Review rounds are what stretch it.

Timelines from the live price table

Our published fixed-scope pricing lists typical timelines of 3 to 5 weeks for a restyle in place, 6 to 8 weeks for a brochure site of 5 to 8 pages, 8 to 13 weeks for a business site of 10 to 16 pages and 14 to 20 weeks for a site plus content program of 30 to 60 pages. Our website design and development page says overruns are almost always caused by content and approvals rather than development, which is why a biotech build with many reviewers should plan its review dates at the start.

What you own at the end

Our website design page lists the deliverables as the site, the accounts in your name, the source files, the documentation. Source files come with final payment on every tier, along with recorded training, and post-launch support runs 14 days on a restyle, 30 days on a brochure or business site and 60 days on a content program. Hosting and maintenance are separate and optional.

How to choose a biotech web design agency

A biotech web design agency should be able to explain how it works with scientific and regulatory reviewers as clearly as it explains its design process. Whether you are comparing a specialist or a general agency, the questions below separate them quickly.

Questions to ask

Ask who reviews scientific accuracy, how approvals are recorded, who owns the accounts and files, how pipeline updates are made, how accessibility is tested and what happens after launch. Ask to see how a change is approved and published, not just a design. A strong answer names roles and records, and a weak one says the details will be agreed later.

Red flags

Each of these leaves the company with more risk than it started with:

• Stock science imagery in place of real labs and people.
• Efficacy or safety language on pipeline pages, written by a designer.
• No review workflow, and no record of who approved a page.
• Accounts and files held in the agency’s name.
• A pipeline chart delivered as a flat image.

What does biotech website design cost?

The scope sets the price of biotech website design: the number of pages and templates, the amount of illustration or animation, integrations such as an investor feed or applicant tracking, and how many rounds of review the content needs.

Our prices

These are the fixed-scope starting prices on our website design and development page. Each price is a starting point written “from”, and the proposal sets the final figure after a written scope. Hosting and maintenance are separate and optional.

What the market charges

The next table reports what other providers publish, across the full spread of their sources. It is not a Progression quote and not a biotech rate:

What moves the price

Four things move a biotech quote more than the rest. Page count drives templates and writing. Illustration and animation add design and scientific review time. Integrations such as an investor feed or an applicant tracking system add build and testing. Review rounds add calendar time and revisions. Keeping the first launch to the pages the company can approve now, and adding trial and investor pages as they become real, is the simplest way to control all four.

Related pages on life science and website work:

• Life sciences marketing
• Pharma branding
• Pharma SEO
• Medical device marketing
• B2B website design
• Website design and development

Frequently asked questions